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Abstract
Background: Nitric oxide (NO) is a free radical that is involved in carcinogenesis. Endothelial NO, synthesized from
L-arginine by endothelial NO synthase (eNOS), inhibits apoptosis and promotes angiogenesis, tumor cell
proliferation and metastasis. The aim of this study was to evaluate the influence of polymorphisms in the eNOS
gene on prognosis of patients with advanced stage non-small-cell lung cancer (NSCLC).
Methods: Unresectable, chemotherapy naïve stage III or IV NSCLC patients who were treated with standard
platinum-containing doublet regimens were analyzed. All individuals were genotyped for the single-nucleotide
polymorphism G894T in exon 7 of the eNOS gene and for a variable number of tandem repeats (VNTR)
polymorphism in intron 4 that results in a rare smaller allele (a) and a common larger allele (b), to investigate the
association between these polymorphisms and clinical outcomes. The primary endpoint was correlation with
overall survival.
Results: From October 2004 to December 2007, 108 patients (male/female, 66/42; Stage IIIA/IIIB/IV, 6/30/72) aged
29-77 years (median 63) with good performance status were consecutively enrolled in this study. Using Kaplan-
Meier estimates, we showed that 5-year overall survival was significantly increased in patients carrying the VNTR a-
allele compared with VNTR b/b patients (P = 0.015). In multivariate Cox proportional hazard analysis, the VNTR
polymorphism was an independent prognostic factor for survival.
Conclusions: The results support the role of the VNTR polymorphism in intron 4 as a marker for survival in
patients with advanced stage NSCLC who are candidates for standard chemotherapy.
Background
Lung cancer is the leading cause of cancer-related death
in most developed countries [1]. Non-small-cell lung
cancer (NSCLC) accounts for 80% of all lung cancers,
and platinum-based chemotherapy is considered the
standard of care worldwide for patients with advanced
stage disease [2]. The treatment response is related to
various factors, most of which are defined by tumor and
clinical characteristics, such as disease stage and perfor-
mance status. However, recent studies have shown that
genetic factors may also influence the effectiveness of
treatment [3,4].
Nitric oxide (NO) is a small free radical and is
involved in numerous physiologic and pathophysiologic
processes, including vasodilation, neurotransmission,
immunity and carcinogenesis. NO is synthesized from
L-arginine and oxygen by four major isoforms of NO
synthase (NOS): neuronal NOS, endothelial NOS
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Although eNOS produces low levels of NO, many clini-
cal observational studies have shown a dysregulation of
eNOS expression in human solid tumors [5].
The number of reported polymorphisms in the gene
encoding eNOS (NOS3) exceeds 160. The G894T poly-
morphism (rs1799983), which is located in exon 7 of
the gene and leads to the amino acid change from
Glu298Asp, is associated with reduced basal NO pro-
duction [6]. In addition, a 27-bp variable number of tan-
dem repeat (VNTR) polymorphism in intron 4 has been
associated with variations in plasma levels of NO and its
metabolites [7,8]. This polymorphism has three alleles: a
short 4 repeat allele (a-allele), a more common long 5
repeat allele (b-allele), and a rare allele with 6 repeats.
Recent studies have indicated that this repeat poly-
morphism in intron 4 is the source of a 27 nt-long RNA
derived from pre-mRNA splicing. This RNA species
inhibits eNOS expression and may represent a new class
of small RNA [9,10]. Endothelial cells containing the a-
allele produce a lower level of 27-nt small RNA and a
higher level of eNOS mRNA compared with cells with
the more common b-allele [10]. The association
between eNOS mRNA levels and the a-allele appeared
to be dose-dependent [11].
To date, very few studies have investigated the asso-
ciation of these polymorphisms with the prognosis of
various neoplastic disorders, and no studies have exam-
ined them in relation to survival of advanced stage
NSCLC patients who are candidates for standard plati-
num-based chemotherapy. In this study, we evaluated
the potential association between these polymorphisms
and survival of NSCLC patients.
Methods
One hundred and eight patients who were judged to
have inoperable stage III or IV NSCLC at the time of
diagnosis were consecutively enrolled in our study
between October 2004 and December 2007. All patients
were native-Japanese of Asian ethnicity. Staging was
based upon the 6th tumor node metastasis (TNM) sta-
ging system [12]. Patients with symptomatic brain
metastasis, malignancies other than NSCLC within the
last 5 years, presence of acute or chronic infections ren-
dering them unsuitable for chemotherapy, or an Eastern
Cooperative Oncology Group (ECOG) performance sta-
tus (PS) of between 2 and 4 were excluded from the
study. Patients with operable disease were also excluded,
because surgery was considered to be a substantial con-
founding factor that masks the genetic effect on survival.
Tumor response was evaluated according to the
Response Evaluation Criteria in Solid Tumors (RECIST)
[13], and all responses were evaluated at least 4 weeks
after initial assessment. The local ethical committee
(Kyoto University Graduate School and Faculty of Medi-
cine, Ethics Committee) approved the study, and written
informed consent was obtained from each patient before
enrollment. The study was conducted in accordance
with the Helsinki declaration.
T h ep a t i e n t sr e c e i v e do n eo ft h ef o l l o w i n gt h r e ec h e -
motherapy treatments: carboplatin/paclitaxel, carbopla-
tin/gemcitabine or cisplatin/gemcitabine. With regard to
the carboplatin/paclitaxel regimen, paclitaxel was admi-
nistered either at a lower dose (70 mg/m2) on a weekly
b a s i sf o r3o u to f4w e e k s ,o ra t1 8 0m g / m 2o nd a y1
(carboplatin dose was area under the curve (AUC) = 5
or 6 mg/mL ￿ min on day 1). The combination of car-
boplatin and gemcitabine consisted of carboplatin AUC
5 mg/mL ￿ min on day 1 plus gemcitabine 1000 mg/m2
on days 1 and 8 every 3 weeks. Carboplatin was
replaced with cisplatin (80 mg/m2 on day 1) in the cis-
platin/gemcitabine regimen. Each treatment was
repeated for three to six cycles, unless unacceptable
toxicity or disease progression was apparent. Patients
who are candidate of definite thoracic irradiation ther-
apy received carboplatin AUC 5 mg/mL ￿ min on day 1
plus paclitaxel 40 mg/m2 on days 1, 8 and 15 every 4
weeks in a concurrent fashion. Two to four cycles of
carboplatin/paclitaxel were administered subsequently
for consolidation.
Blood samples were collected and DNA was isolated
from whole blood cell fractions using the QIAamp DNA
Blood Mini Kit (Qiagen, Tokyo, Japan). The single
nucleotide polymorphism (SNP) of G894T (a G-to-T
transversion at nucleotide 894 in exon 7) was analyzed
with TaqMan genotyping assays, using the ABI 7500
real-time PCR system (Applied Biosystems, Inc., Tokyo,
Japan). Probes, primers and TaqMan universal PCR
master mix were those from ABI and TaqMan assays
were performed according to the manufacturer’s instruc-
tions. The intronic 27 bp insertion/deletion VNTR was
genotyped using PCR amplification and agarose gel elec-
trophoresis with ethidium bromide staining [14].
The distribution of genotypes was tested for Hardy-
Weinburg equilibrium with the goodness-of-fit c
2 test.
The linkage disequilibrium of the two polymorphisms
was analyzed. The association between overall survival
times was estimated using the Kaplan-Meier method
and assessed using the log-rank test. The effects of dif-
ferent genotypes on overall survival were estimated
using hazard ratios (HRs), and 95% confidence intervals
(95%CIs) were estimated using the multivariate Cox
proportional hazards regression model, with adjustment
for gender, age (<70 vs. older), ECOG PS (0 vs. 1),
smoking status (never-smoker vs. former/current smo-
k e r ) ,c l i n i c a ls t a g e( I I Iv s .I V ) ,h i s t o l o g y( a d e n o c a r c i -
n o m av s .o t h e r s ) ,t h o r a c i c radiotherapy (yes vs. no)
and the two genotypes examined. We used Akaike’s
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able in a stepwise Cox regression [15]. Survival time was
calculated from diagnosis to death or last follow-up. A P
value of <0.05 was considered statistically significant.
We estimated the false-positive report probability for
the observed statistically significant associations using
the methods described by Wacholder et al [16]. HR
values from 2.0 to 4.0 were considered likely threshold
values. The prior probability used was 0.1 for these
polymorphisms and the false-positive report probability
value for noteworthiness was set at 0.5.
Statistical analyses were performed using JMP version
6 (SAS Institute, Cary, NC, USA.), R software (R Foun-
dation for Statistical Computing., Vienna, Austria.), and
Haploview version 4.0 [17].
Results
Patients’ characteristics are summarized in Table 1.
Eighty percent of patients had a cytological or histologi-
cal diagnosis of adenocarcinoma. Treatment characteris-
t i c sa r es h o w ni nT a b l e2 .B yJ u l y3 1 ,2 0 0 9 ,7 3( 6 8 % )o f
the 108 patients had died. The median follow-up period
was 21.5 months.
Median survival for all 108 patients was 26.8 months
(95%CI, range 21.9 - 30.7 months). Median survival was
23.3 months for male patients and 32.3 months for
female patients (HR, 1.72; 95%CI, 1.04-2.85; P = 0.034).
Median survival was 24.6 months for smokers and 35.2
months for never-smokers (HR, 1.69; 95%CI, 1.00-2.85;
P = 0.048). There was substantial agreement between
gender and smoking status (Cohen’s kappa coefficient,
0.64). Age, ECOG PS, disease stage, histology, and thor-
acic radiotherapy were not significantly associated with
overall survival in the univariate analysis. Regarding epi-
dermal growth factor receptor (EGFR) gene mutations,
tumor samples of 34 patients (31.5%) were analyzed and
21 were positive for mutations. Eleven tumors had an
L858R mutation in exon 21 and nine contained in-
frame nucleotide deletions (including E746-A750) in
exon 19. A G719S mutation was found in one tumor.
EGFR mutation status (positive vs. negative/unknown)
was not prognostic in the univariate analysis.
The distribution of all genotypes and allelic frequen-
cies is shown in Table 3. These frequencies were in
agreement with previous reports, and with those
expected according to the Hardy-Weinburg equilibrium
model. Linkage disequilibrium between these poly-
morphisms was not observed. Since there was no TT
homozygote carrier with respect to G894T, and analyses
were performed between the GG homozygote group and
the GT heterozygote group. In addition, because the fre-
quency of intron 4 short repeat (a-allele) homozygotes
was low (0.9%; n = 1), b/a heterozygotes and a/a homo-
zygotes were combined into an a-allele carrier group for
analyses.
Median survival was 36.8 months for a-allele carriers
and 23.4 months for b/b homozygotes (Figure 1). The
univariate Cox regression model showed that presence
of the a-allele significantly correlated with prolonged
survival (HR, 0.47; 95% CI, 0.25-0.88; P = 0.015). Corre-
spondingly, carriers of the common b/b genotype had a
Table 1 Characteristics of the 108 patients with non-
small-cell lung cancer enrolled in the study
Patients
N%
Age, Years
Median 63
Range 29 - 77
Gender
Male 66 61.1
Female 42 38.9
Stage
IIIA 6 5.5
IIIB 30 27.8
IV 72 66.7
PS
0 23 21.3
1 85 78.7
Chemotherapy regimen
CBDCA+PAC 89 82.4
CBDCA+GEM 17 15.7
CDDP+GEM 2 1.9
Definitive thoracic radiotherapy
Yes 20 18.5
No 88 81.5
Abbreviations: CBDCA, carboplatin; PAC, paclitaxel; CDDP, cisplatin; GEM,
gemcitabine
Table 2 Treatment characteristics of the enrolled patients
No. of patients
Stage IIIA Stage IIIB Stage IV
CBDCA + PAC + TRT 6 14 0
CBDCA + PAC 0 13 56
CBDCA + GEM 0 3 14
CDDP + GEM 0 0 2
Abbreviations: TRT, thoracic radiotherapy
Table 3 Genotypic and allelic frequencies of the G894T
SNP in exon 7 and the VNTR in intron 4
Genotypic frequencies (%) Allelic frequencies (%)
G894T GluGlu GluAsp AspAsp Glu Asp
84.3 15.7 0 92.1 7.9
VNTR in intron 4 bb ba aa b a
80.6 18.5 0.9 89.8 10.2
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2.14). The false-positive report probability for the VNTR
was 0.16, indicating noteworthiness. No significant dif-
ference in survival was observed according to the
G894T SNP (P = 0.28) (Figure 2).
EGFR mutation status was not included in a Cox pro-
portional hazards model because the number of ana-
lyzed patients was small and statistically significant
results were not observed in the univariate analysis.
Including gender, age, ECOG PS, smoking status, clini-
cal stage, histology, thoracic radiotherapy and two geno-
types in a model, the common b/b genotype (HR, 2.33;
95% CI, 1.24 - 4.36; P = 0.0085), male gender (HR, 2.02;
95% CI, 1.20-3.43; P = 0.0084) and stage IV disease (HR,
1.76; 95% CI, 1.04-2.99; P = 0.036) were selected as the
predictors for overall survival. Correspondingly, HRs of
female gender and stage III disease were 0.50 and 0.57,
respectively.
With regard to clinical and pathological parameters,
there were no discrepancies between carriers of the
VNTR common b/b genotype and the VNTR a-allele
carriers (Table 4). To investigate whether the eNOS
intron 4 VNTR was associated with clinical benefit of
chemotherapy, we analyzed the treatment response
among patients without definitive thoracic radiotherapy.
The overall response rate in 82 evaluable patients was
27%, with 22 (27%) partial responders (PR), 50 patients
(61%) with stable disease (SD), and 10 patients (12%)
with disease progression (PD). There was no significant
distribution of a-allele carriers when patients were sepa-
rated into two groups (PR+SD group vs. PD group;
Table 5), indicating that the effect of the polymorphism
on survival was not associated with the clinical benefit
of first-line platinum-containing chemotherapy. We
restricted the population to patients who received carbo-
platin plus paclitaxel without definitive thoracic radio-
therapy and re-analyzed. The PR+SD rate was 81% in
a-allele carriers and 86% in b/b genotype patients,
respectively. Again there was no significant difference
between the groups (P = 0.69).
Discussion
Our results show that polymorphism of the 27-bp
VNTR in intron 4 of the eNOS gene is strongly asso-
ciated with survival in advanced stage NSCLC patients
treated with standard platinum-based chemotherapy.
Median survival was significantly prolonged in patients
carrying the shorter a-allele (i.e., those with a higher
level of eNOS mRNA production).
Published studies indicate a procarcinogenic role of
eNOS. In solid tumors, eNOS plays an essential role in
VEGF-induced angiogenesis and vascular permeability
[18]. A recent study showed that blocking phosphoryla-
tion of eNOS inhibited tumor initiation and mainte-
nance through inactivation of the PI3K-AKT-eNOS-RAS
pathway [19]. Moreover, a higher eNOS level was shown
to correlate with cisplatin resistance in ovarian cancer
cell lines [20]. Our findings were unexpected and in
contrast to these observations.
However, our results can be explained by considering
the following factors. NO derived from eNOS or eNOS
itself can be cytotoxic to cancer cells through direct
DNA damage and can be antitumorigenic [21]. The
cytotoxic effects of NO can also be mediated through
the generation of peroxynitrite (ONOO-) in the pre-
s e n c eo fs u p e r o x i d ea n i o n( O ∙2-) [22]. Moreover, clear-
ance of metastatic cells from organ microvasculature is
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Figure 1 Kaplan-Meier plot of overall survival in relation to the
VNTR genotype
0 1 22 43 64 86 0
0
.2
.4
.6
.8
1.0
GluGlu
GluAsp
Overall survival (months)
P
r
o
b
a
b
i
l
i
t
y
P=0.28 by log−rank test
Figure 2 Kaplan-Meier plot of overall survival in relation to the
G894T genotype in exon 7
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reduce the attachment of tumor cells to the endothe-
lium and NO-mediated vasodilation may also contribute
to the clearance of tumor cells [23,24]. Using an eNOS
knockout mice model and the B16F1 melanoma cell
line, Wang and colleagues have shown that arrest of
tumor cell metastasis in the portal and pulmonary circu-
lation can trigger the immediate release of NO in an
eNOS-dependent manner, and subsequently induce
apoptosis in these tumor cells [25,26]. Our observations
were consistent with these reports. Furthermore, Mor-
tensen et al. showed that expression of immunoreactive
eNOS in the peritumoral microvasculature is a favorable
prognostic indicator in premenopausal breast cancer
patients, providing clinical evidence for a defensive role
of eNOS against cancer cells [27]. With respect to
treatment modality, NO was shown to increase the effi-
cacy of chemotherapy and improve survival of patients
with NSCLC in one phase II trial. Yasuda et al. rando-
mized 120 patients with advanced stage NSCLC to
receive standard chemotherapy (cisplatin and vinorel-
bine) alone, or the same regimen with nitroglycerin, a
NO-donating drug [28]. The median time to progression
was longer (10.9 vs. 6.2 months) in the nitroglycerin
treatment group. Thus, in certain situations NO appears
to act as a defense against the progression and/or
metastasis of malignant tumors.
The median survival time of 26.8 months observed in
the present study was favorable compared with that
described in other reports [29,30]. This is probably due
to the inclusion of a heterogeneous treatment group
(including patients who received definitive chemoradia-
tion) and the relatively young population (median 63
years of age).
Our study has several limitations. The single-institu-
tional study design contains the potential to introduce a
selection bias. Although we estimated the false-positive
report probability to confirm the statistical significance
obtained by established methods, analysis based upon a
small number of enrolled patients could potentially lead
to false-positive results. Two recent Japanese trials
Table 4 Comparative analysis of demographic and pathological information
No. of bb genotype pts. No. of a-allele carriers P
Gender
Female 35 7 P = 0.63
Male 52 14
Age
<70 64 15 P > 0.9
70 or older 23 6
ECOG PS
0 17 6 P = 0.38
17 0 1 5
Smoking Status
Never or Light 29 7 P > 0.9
Current or Former 58 14
Clinical Stage
III 31 5 P = 0.44
IV 56 16
Histology
Adenocarcinoma 68 18 P = 0.56
Non-adenocarcinoma 19 3
EGFR mutation
Activating mutation 19 2 P = 0.30
Wild type 9 4
Unknown 59 15
Thoracic radiotherapy
Yes 17 3 P = 0.76
No 70 18
Table 5 Frequency and distribution of eNOS intron 4
VNTR alleles in 72 patients with partial response or
stable disease and 10 patients with progressive disease
PR+SD PD
No. of Patients % No. of Patients % P
a-allele carriers 15 83 3 17 0.68
bb genotype 57 89 7 11
Fujita et al. BMC Medical Genetics 2010, 11:167
http://www.biomedcentral.com/1471-2350/11/167
Page 5 of 7confirmed that EGFR mutation status is a predictive fac-
tor for response to EGFR-TKI treatment with a progres-
sion free survival of 10 months [31,32] and this finding
paves the way for the personalized therapy for NSCLC.
EGFR mutation status was evaluated in only a small
proportion of the enrolled patients (31.5%) and the
favorable effect of the mutations on prognosis was not
observed in our study. Finally, because we restricted the
study subjects to those of East-Asian ethnicity, it is
uncertain whether these results can be generalized to
other populations.
Conclusions
Our results indicate that the VNTR polymorphism in
intron 4 of the eNOS gene may be associated with the
progression of NSCLC and shed light on the association
between polymorphisms in the eNOS gene and survival
of patients with NSCLC.
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